How Long Does Suboxone Stay in Your System?

Suboxone stays in your system for 7 to 10 days after the last dose.

The active ingredient, buprenorphine, has a half-life of 24 to 42 hours, meaning it takes roughly five half-lives, or five to nine days, for the drug to clear the body fully. Its metabolite norbuprenorphine has an even longer half-life of up to 150 hours and may remain detectable in urine for up to 14 days.

Detection windows vary significantly depending on the test type used, the dose, how long you have been taking Suboxone, and several individual biological factors. The answer is different for a single dose than for someone on long-term maintenance treatment.

What is your reason for needing to know how long Suboxone stays detectable?

Key Takeaways

• Buprenorphine, the active ingredient in Suboxone, has a half-life of 24 to 42 hours, making it one of the longest-acting opioids in the drug supply and significantly longer-acting than heroin, oxycodone, or fentanyl.
• Suboxone is detectable in urine for 7 to 10 days after the last dose, in blood for up to 2 days, in saliva for up to 3 days, and in hair for up to 90 days, according to ARUP Laboratories drug detection data.
• Norbuprenorphine, the primary metabolite produced when the liver breaks down buprenorphine, has a half-life of up to 150 hours and can extend urine detectability to 14 days in chronic high-dose users.
• Standard 5-panel and 10-panel drug tests do not screen for buprenorphine. Suboxone only appears on tests that specifically include a buprenorphine or opioid treatment medication panel.
• In people with moderate to severe liver disease, buprenorphine’s half-life increases by up to 57% and naloxone’s by up to 122%, substantially extending the clearance timeline.

Suboxone Half-Life: Understanding the Basics

The half-life of a drug is the time it takes for the body to eliminate half of one dose from the bloodstream. Suboxone contains two active ingredients with very different half-lives, and understanding both is necessary to understand how long Suboxone stays in the system.

Buprenorphine, the primary therapeutic ingredient, has a half-life of 24 to 42 hours. This is dramatically longer than most opioids, which is precisely why buprenorphine can be taken once daily rather than multiple times per day. At a full five half-lives, buprenorphine clears the system in approximately 120 to 210 hours, or 5 to 9 days.

Naloxone, the abuse-deterrent component in Suboxone, has a much shorter half-life of 2 to 12 hours. It clears the body within approximately 24 to 60 hours. Because naloxone is not a drug of abuse and is not pharmacologically active when Suboxone is taken sublingually as prescribed, drug testing programs do not typically test for naloxone.

Norbuprenorphine: The Metabolite That Stays Longer

When the liver metabolizes buprenorphine, it produces a primary metabolite called norbuprenorphine. This metabolite has a half-life of up to 150 hours, substantially longer than the parent drug. Norbuprenorphine is also active at opioid receptors and can be detected in urine drug tests for up to 14 days in people with chronic high-dose Suboxone use.

This means that even after buprenorphine itself has cleared the system, norbuprenorphine may still produce a positive result on a buprenorphine-specific urine panel. For patients who are actively prescribed Suboxone, this is clinically expected. For people attempting to determine clearance for other reasons, the 7 to 10-day urine window is the conservative estimate, and the 14-day window applies to heavy or long-term users.

Detection Windows by Test Type

The following table summarizes Suboxone detection windows across all four standard testing methods.

Test Type	When Detectable	Detection Window	Notes
Urine	2 to 4 hours after dose	7 to 10 days (up to 14 days for norbuprenorphine)	Most commonly used; requires buprenorphine-specific panel
Blood	Within 30 to 60 minutes	Up to 2 days (48 hours)	Most accurate within 2 hours of dosing; rarely used for Suboxone monitoring
Saliva	Within 30 minutes	Up to 3 days (72 hours)	Less sensitive than urine; useful for recent-use detection
Hair	7 to 10 days post-dose	Up to 90 days	Most expensive; rarely used clinically; reflects long-term exposure history

Urine Test Detection

Urine testing is the standard method used in opioid treatment programs to monitor Suboxone adherence and confirm compliance. The test does not detect Suboxone itself but rather its metabolites, primarily norbuprenorphine, which persist in urine substantially longer than the parent compound.

A person on a stable maintenance dose will consistently test positive on a buprenorphine-specific urine panel. A person who misses doses will show declining or absent levels. The 7 to 10-day window applies to people who have been taking Suboxone regularly. A single dose from a person who was not previously on the medication may clear urine within three to five days.

Does Suboxone Show Up on a Standard Drug Test?

Standard 5-panel and 10-panel urine drug tests, which are the most common type used for employment screening, do not include buprenorphine. These panels typically screen for amphetamines, cocaine, THC, opiates (via morphine antibodies), and PCP, and sometimes benzodiazepines, opioids, or barbiturates depending on the panel.

Buprenorphine is chemically distinct from the opioids that standard opiate panels detect and will not produce a positive result on a test screening for heroin, oxycodone, or codeine. Suboxone only appears positive on tests that specifically include a buprenorphine or buprenorphine metabolite component. These specialized panels are used in treatment programs, pain management monitoring, and some legal or custody situations.

Factors That Affect How Long Suboxone Stays in Your System

Dose and Frequency of Use

The higher the prescribed Suboxone dose and the longer the duration of treatment, the more buprenorphine and norbuprenorphine accumulate in tissue and the longer clearance takes. A person taking 24mg daily for two years will have a substantially larger metabolite burden than someone who just started at 4mg. Long-term maintenance patients should expect detection windows at the upper end of the 7 to 14-day urine range.

Liver Function

Buprenorphine is metabolized entirely by the liver through CYP3A4 enzyme activity. In people with moderate liver disease, buprenorphine’s half-life increases by approximately 57% and naloxone’s by approximately 122%, compared to people with healthy liver function. In severe liver disease, clearance can extend the total elimination timeline to 7 to 14 days for buprenorphine and up to several weeks for norbuprenorphine accumulation.

Metabolism, Age, and Body Composition

Older adults generally metabolize buprenorphine more slowly than younger adults. Buprenorphine is lipophilic, meaning it distributes into fatty tissue. People with higher body fat percentages may retain buprenorphine and its metabolites in tissue for longer, gradually releasing them back into circulation and extending detection windows. Individual metabolic rate, hydration status, and urine pH also influence renal excretion of metabolites.

Formulation: Film, Tablet, or Sublocade

Standard sublingual Suboxone film and tablets have the same detection windows described above. Sublocade, the extended-release injectable formulation of buprenorphine, is administered as a monthly subcutaneous injection that maintains continuous buprenorphine blood levels without daily dosing. Because Sublocade releases buprenorphine slowly over the entire month, its detection window in urine extends for the full duration of the injection cycle and beyond. Patients receiving Sublocade should expect buprenorphine to be continuously detectable in urine testing throughout their treatment and for several weeks following their final injection.

What Is the Washout Period for Suboxone?

The Suboxone washout period refers to the time required after stopping Suboxone before transitioning to another opioid medication, particularly naltrexone (Vivitrol). Naltrexone is a full opioid antagonist, and administering it while buprenorphine still occupies opioid receptors causes precipitated withdrawal.

For patients transitioning from Suboxone to naltrexone, most clinical protocols require a minimum of seven days of abstinence from Suboxone before starting the first naltrexone dose, with many protocols recommending 10 to 14 days to ensure complete receptor clearance. Given buprenorphine’s long half-life and tissue accumulation, this washout period is clinically necessary and should be managed under direct medical supervision with withdrawal symptom support during the transition window.

What Is the 3-Day Suboxone Rule?

The Suboxone 3-day rule is a DEA regulatory provision under 21 CFR Part 1306.07(b) that allows any licensed physician, including emergency room physicians and primary care providers who are not registered or waivered to prescribe Suboxone for addiction treatment, to administer Suboxone or buprenorphine to a patient experiencing acute opioid withdrawal for up to 72 hours.

The rule allows no more than one day’s medication to be administered at a time, cannot be renewed or extended, and requires the provider to actively arrange referral to a certified treatment program during the 72-hour window. It is not a prescription and not a substitute for ongoing treatment. It exists specifically to bridge the gap between acute withdrawal crisis and access to structured care, ensuring patients can receive immediate pharmacological stabilization without waiting for a specialist appointment.

What Is the Suboxone Spit Trick?

The spit trick refers to spitting out residual saliva after a Suboxone film has fully dissolved under the tongue, rather than swallowing it. This is actually clinically appropriate and recommended by many providers. The reason is pharmacological: buprenorphine is absorbed through the sublingual mucosa during dissolution, not through the gastrointestinal tract. Once the film has dissolved completely, the remaining saliva contains primarily inactive filler ingredients, residual naloxone, and a small amount of unabsorbed buprenorphine.

Swallowing this residual saliva does not increase buprenorphine’s therapeutic effect, because buprenorphine has very poor oral bioavailability when ingested. However, swallowing opioid-containing residue can stimulate opioid receptors in the gut, contributing to nausea, constipation, and abdominal discomfort. Spitting out the saliva after full dissolution reduces these GI side effects without reducing the therapeutic dose.

What constitutes misuse is spitting out the medication before it has fully dissolved, which reduces absorption and undermines the therapeutic dose. The correct application is to allow complete dissolution for five to fifteen minutes before spitting out residual saliva.

Treatment for Opioid Use Disorder

If you are taking Suboxone as part of an opioid use disorder treatment program, the detection windows in this article reflect what is clinically normal and expected. If you are researching Suboxone because you or someone you love is managing opioid dependence and needs structured support, the following programs are available through New Spirit Recovery.

Medication-Assisted Treatment

Our medication-assisted treatment program integrates buprenorphine-naloxone prescription with evidence-based behavioral therapy and clinical monitoring. Suboxone is most effective when combined with therapy that addresses the psychological and behavioral dimensions of opioid use disorder alongside the pharmacological stabilization the medication provides.

Medical Detox

For patients transitioning off Suboxone, initiating Suboxone from a cold-start withdrawal, or navigating the washout period before starting naltrexone, our medical detox program provides 24-hour nursing supervision and physician-directed care throughout stabilization. Buprenorphine’s long half-life makes the transition between medications clinically complex, and medical oversight prevents precipitated withdrawal during these transitions.

Dual Diagnosis Treatment

Many people on Suboxone are also managing untreated anxiety, depression, PTSD, or trauma. Our dual diagnosis program treats both the opioid use disorder and co-occurring psychiatric conditions within the same integrated clinical framework. Untreated mental health conditions are the most consistent driver of relapse even in people who are pharmacologically stabilized on buprenorphine.

Residential Treatment

Our residential treatment program provides the fully supervised, structured environment where the earliest and most neurologically vulnerable phase of opioid recovery proceeds safely. Daily clinical programming runs seven days a week, with individual therapy, group therapy, and medical monitoring built into every day of treatment.

Contact our admissions team through the admissions process page for a confidential clinical assessment. Same-day assessments are available for individuals ready to begin treatment today.

Frequently Asked Questions

What is the washout period for Suboxone?

The Suboxone washout period is the time required after stopping buprenorphine before starting naltrexone (Vivitrol). Most clinical protocols require a minimum of seven days of abstinence from Suboxone before the first naltrexone dose, with many recommending 10 to 14 days for patients on higher doses or long-term maintenance. Administering naltrexone before buprenorphine has fully cleared the receptors causes precipitated withdrawal. The washout must be medically supervised.

How long is Suboxone detectable in your urine?

Suboxone is detectable in urine for 7 to 10 days after the last dose on a buprenorphine-specific urine panel. The metabolite norbuprenorphine has a longer half-life and may extend detection to 14 days in chronic high-dose users. Standard employment drug tests do not screen for buprenorphine and will not detect Suboxone at all. Only specialized panels that specifically include buprenorphine or its metabolites will produce a positive result.

What is the 3-day Suboxone rule?

The 3-day Suboxone rule is a DEA regulatory provision that allows any licensed physician to administer Suboxone or buprenorphine for up to 72 hours to a patient in acute opioid withdrawal, even without the specialized registration normally required to prescribe it for addiction treatment. No more than one day’s medication may be given at a time, and the provider must arrange referral to a certified treatment program during the 72-hour window. It is a bridge to structured care, not a replacement for it.

What is the spit trick for Suboxone?

The spit trick refers to spitting out residual saliva after a Suboxone film has fully dissolved under the tongue. Once dissolution is complete, the remaining saliva contains inactive fillers rather than therapeutically active buprenorphine, since the drug is already absorbed through the sublingual mucosa. Spitting out this residue reduces gastrointestinal side effects like nausea and constipation without reducing dose effectiveness. The medication must be allowed to dissolve completely (five to fifteen minutes) before spitting. Spitting before dissolution is misuse and reduces the therapeutic dose.

Does Suboxone show up on a standard drug test?

No. Standard 5-panel and 10-panel employment urine drug tests do not screen for buprenorphine. Suboxone only appears positive on tests that specifically include a buprenorphine or norbuprenorphine panel. These are used in treatment programs and certain legal or clinical contexts, not in routine employment screening. Suboxone will not produce a false positive for heroin, oxycodone, or other opioids on a standard panel because buprenorphine is chemically distinct from the compounds those tests detect.

How long does 2mg Suboxone stay in your system?

A lower dose of 2mg buprenorphine will generally clear urine detection thresholds at the shorter end of the 7 to 10-day window, typically closer to five to seven days, assuming normal liver and kidney function. The half-life of buprenorphine does not change with dose, but a smaller dose produces a lower metabolite burden that the kidneys clear more quickly. Factors including metabolism, hydration, body composition, and the sensitivity of the specific test panel used will all influence the exact detection window.

References

1. ARUP Laboratories. (2023). Drug plasma half-life and urine detection window. https://www.aruplab.com/files/resources/pain-management/DrugPlasmaHalf-LifeandUrineDetectionWindow.pdf
2. Drugs.com. (2025). How long does Suboxone stay in your system? https://www.drugs.com/medical-answers/long-suboxone-stay-system-3535350/
3. Sevarino, K. A. (2023). Buprenorphine. In StatPearls. StatPearls Publishing.
4. Drug Enforcement Administration. (2023). Title 21, Code of Federal Regulations, Part 1306.07(b) — Three-day rule. https://www.deadiversion.usdoj.gov/drugreg/faq.htm
5. Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder: Treatment improvement protocol 63. https://store.samhsa.gov/product/tip-63-medications-opioid-use-disorder/PEP21-02-01-002
6. Belivanis, S., et al. (2014). Buprenorphine and nor-buprenorphine levels in hair samples from patients under Suboxone treatment. Drug Testing and Analysis, 6(7-8), 788-794.
7. Hallare, J., & Gerriets, V. (2023). Half life. In StatPearls. StatPearls Publishing.